If approved, Arena will have the first true weightloss drug on the market since Meridia was pulled because of safety concerns in 2010. It leapfrogged competitor VIVUS ( NAS: VVUS ) when the FDA asked for a risk evaluation and mitigation strategy for its drug Qnexa. However, I see both VIVUS and Orexigen ( NAS: OREX ) jumping if lorcaserin is given the green light, with an indication the FDA has softened its stance on the space.